Generic Name: anakinra
Brand Name: Kineret
Manufacturer: Swedish Orphan Biovitrum AB
Therapeutic Area: Still's disease
Indications: For the treatment of Still’s disease with active systemic features, in adults and pediatric patients aged 8 months and older with a body weight of 10 kg or above.
Manufacturer Requested Reimbursement Criteria1: For the treatment of Still’s disease with active systemic features, in adults and pediatric patients aged 8 months and older with a body weight of 10 kg or above.
Submission Type: Initial
NOC Status at Filing: Pre NOC
Project Status: Active
Companion Diagnostics: No
Fee Schedule: Schedule A
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Key Milestones2 | |
|---|---|
| Call for patient/clinician input open | November 16, 2020 |
| Call for patient/clinician input closed | January 15, 2021 |
| Clarification: - Patient input submission received from Arthritis Consumer Experts and Canadian Arthritis Patient Alliance / Arthritis Society/ Cassie and Friends | |
| Submission received | December 21, 2020 |
| Submission accepted | January 12, 2021 |
| Review initiated | January 13, 2021 |
| Draft CADTH review report(s) provided to sponsor for comment | March 29, 2021 |
| Deadline for sponsors comments | April 08, 2021 |
| CADTH responses on draft review report(s) provided to sponsor | May 07, 2021 |
| Expert committee meeting (initial) | May 19, 2021 |
| Draft recommendation issued to sponsor | June 01, 2021 To June 03, 2021 |